-
1
-
-
58149114715
-
Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity
-
Adermark L, Talani G, Lovinger DM, (2009). Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 29: 32-41.
-
(2009)
Eur J Neurosci
, vol.29
, pp. 32-41
-
-
Adermark, L.1
Talani, G.2
Lovinger, D.M.3
-
2
-
-
39449113020
-
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
-
DOI 10.1016/j.expneurol.2007.10.012, PII S0014488607004025
-
Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, et al,. (2008). Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 210: 182-193. (Pubitemid 351265366)
-
(2008)
Experimental Neurology
, vol.210
, Issue.1
, pp. 182-193
-
-
Alvarez-Fischer, D.1
Henze, C.2
Strenzke, C.3
Westrich, J.4
Ferger, B.5
Hoglinger, G.U.6
Oertel, W.H.7
Hartmann, A.8
-
4
-
-
38349099590
-
The peripheral cannabinoid receptor knockout mice: An update
-
Buckley NE, (2008). The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 153: 309-318.
-
(2008)
Br J Pharmacol
, vol.153
, pp. 309-318
-
-
Buckley, N.E.1
-
5
-
-
0034685707
-
2 receptor
-
DOI 10.1016/S0014-2999(00)00211-9, PII S0014299900002119
-
Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al,. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396: 141-149. (Pubitemid 30265571)
-
(2000)
European Journal of Pharmacology
, vol.396
, Issue.2-3
, pp. 141-149
-
-
Buckley, N.E.1
McCoy, K.L.2
Mezey, E.3
Bonner, T.4
Zimmer, A.5
Felder, C.C.6
Glass, M.7
Zimmer, A.8
-
6
-
-
0033936028
-
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
-
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM, (2000). Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14: 1432-1438. (Pubitemid 30439752)
-
(2000)
FASEB Journal
, vol.14
, Issue.10
, pp. 1432-1438
-
-
Di Marzo, V.1
Hill, M.P.2
Bisogno, T.3
Crossman, A.R.4
Brotchie, J.M.5
-
7
-
-
2442677617
-
Experimental Parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: A modulator of endocannabinoid function
-
DOI 10.1038/sj.npp.1300407
-
Fernández-Espejo E, Caraballo I, Rodriguez de Fonseca F, Ferrer B, El Banoua F, Flores JA, et al,. (2004). Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 29: 1134-1142. (Pubitemid 38670050)
-
(2004)
Neuropsychopharmacology
, vol.29
, Issue.6
, pp. 1134-1142
-
-
Fernandez-Espejo, E.1
Caraballo, I.2
Rodriguez De Fonseca, F.3
Ferrer, B.4
El Banoua, F.5
Flores, J.A.6
Galan-Rodriguez, B.7
-
8
-
-
14744301757
-
1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism
-
DOI 10.1016/j.nbd.2004.10.015
-
Fernández-Espejo E, Caraballo I, Rodríguez de Fonseca F, El Banoua F, Ferrer B, Flores JA, et al,. (2005). Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18: 591-601. (Pubitemid 40332717)
-
(2005)
Neurobiology of Disease
, vol.18
, Issue.3
, pp. 591-601
-
-
Fernandez-Espejo, E.1
Caraballo, I.2
De Fonseca, F.R.3
El Banoua, F.4
Ferrer, B.5
Flores, J.A.6
Galan-Rodriguez, B.7
-
9
-
-
0141481993
-
Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias
-
DOI 10.1046/j.1460-9568.2003.02896.x
-
Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A, (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18: 1607-1614. (Pubitemid 37215113)
-
(2003)
European Journal of Neuroscience
, vol.18
, Issue.6
, pp. 1607-1614
-
-
Ferrer, B.1
Asbrock, N.2
Kathuria, S.3
Piomelli, D.4
Giuffrida, A.5
-
10
-
-
33846401540
-
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties
-
DOI 10.1016/j.brainres.2006.11.063, PII S0006899306034718
-
García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J, (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134: 162-170. (Pubitemid 46135535)
-
(2007)
Brain Research
, vol.1134
, Issue.1
, pp. 162-170
-
-
Garcia-Arencibia, M.1
Gonzalez, S.2
De Lago, E.3
Ramos, J.A.4
Mechoulam, R.5
Fernandez-Ruiz, J.6
-
11
-
-
43549124297
-
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats
-
García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J, (2008). Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438: 10-13.
-
(2008)
Neurosci Lett
, vol.438
, pp. 10-13
-
-
García-Arencibia, M.1
Ferraro, L.2
Tanganelli, S.3
Fernández-Ruiz, J.4
-
13
-
-
33644952242
-
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
-
González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J, (2006). Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073-1074: 209-219.
-
(2006)
Brain Res
, vol.1073-1074
, pp. 209-219
-
-
González, S.1
Scorticati, C.2
García-Arencibia, M.3
De Miguel, R.4
Ramos, J.A.5
Fernández-Ruiz, J.6
-
14
-
-
0037104758
-
Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission
-
Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, et al,. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22: 6900-6907. (Pubitemid 35379148)
-
(2002)
Journal of Neuroscience
, vol.22
, Issue.16
, pp. 6900-6907
-
-
Gubellini, P.1
Picconi, B.2
Bari, M.3
Battista, N.4
Calabresi, P.5
Centonze, D.6
Bernardi, G.7
Finazzi-Agro, A.8
Maccarrone, M.9
-
15
-
-
66049127133
-
Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice
-
Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, et al,. (2009). Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87: 1913-1921.
-
(2009)
J Neurosci Res
, vol.87
, pp. 1913-1921
-
-
Hunter, R.L.1
Cheng, B.2
Choi, D.Y.3
Liu, M.4
Liu, S.5
Cass, W.A.6
-
16
-
-
46149095463
-
The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson's disease
-
Jiménez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C, (2008). The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease. Neurosci Res 61: 404-411.
-
(2008)
Neurosci Res
, vol.61
, pp. 404-411
-
-
Jiménez-Del-Rio, M.1
Daza-Restrepo, A.2
Velez-Pardo, C.3
-
17
-
-
67649644733
-
The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
-
Kelsey JE, Harris O, Cassin J, (2009). The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 203: 304-307.
-
(2009)
Behav Brain Res
, vol.203
, pp. 304-307
-
-
Kelsey, J.E.1
Harris, O.2
Cassin, J.3
-
18
-
-
0035545362
-
1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
-
DOI 10.1046/j.0953-816X.2001.01812.x
-
Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA, et al,. (2001). Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14: 1827-1832. (Pubitemid 35463701)
-
(2001)
European Journal of Neuroscience
, vol.14
, Issue.11
, pp. 1827-1832
-
-
Lastres-Becker, I.1
Cebeira, M.2
De Ceballos, M.L.3
Zeng, B.-Y.4
Jenner, P.5
Ramos, J.A.6
Fernandez-Ruiz, J.J.7
-
19
-
-
17444370570
-
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
-
DOI 10.1016/j.nbd.2004.11.009
-
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J, (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96-107. (Pubitemid 40544727)
-
(2005)
Neurobiology of Disease
, vol.19
, Issue.1-2
, pp. 96-107
-
-
Lastres-Becker, I.1
Molina-Holgado, F.2
Ramos, J.A.3
Mechoulam, R.4
Fernandez-Ruiz, J.5
-
20
-
-
71849104860
-
Protein measurement with the Folin phenol reagent
-
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
-
(1951)
J Biol Chem
, vol.193
, pp. 265-275
-
-
Lowry, O.H.1
Rosebrough, N.J.2
Farr, A.L.3
Randall, R.J.4
-
21
-
-
0027482872
-
Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study
-
DOI 10.1111/j.1471-4159.1993.tb09807.x
-
Mailleux P, Vanderhaeghen JJ, (1993). Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61: 1705-1712. (Pubitemid 23317193)
-
(1993)
Journal of Neurochemistry
, vol.61
, Issue.5
, pp. 1705-1712
-
-
Mailleux, P.1
Vanderhaeghen, J.-J.2
-
23
-
-
2942597453
-
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease
-
DOI 10.1097/00002826-200405000-00003
-
Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, et al,. (2004). Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease. Clin Neuropharmacol 27: 108-110. (Pubitemid 38746008)
-
(2004)
Clinical Neuropharmacology
, vol.27
, Issue.3
, pp. 108-110
-
-
Mesnage, V.1
Houeto, J.L.2
Bonnet, A.M.3
Clavier, I.4
Arnulf, I.5
Cattelin, F.6
Le Fur, G.7
Damier, P.8
Welter, M.L.9
Agid, Y.10
-
24
-
-
38449091547
-
Biochemistry of postmortem brains in Parkinson's disease: Historical overview and future prospects
-
Nagatsu T, Sawada M, (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 72: 113-120.
-
(2007)
J Neural Transm Suppl
, vol.72
, pp. 113-120
-
-
Nagatsu, T.1
Sawada, M.2
-
25
-
-
33846677995
-
An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats
-
DOI 10.1007/s00726-006-0317-y, Special Issue: Focus on Metabotropic Glutamate Receptors
-
Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S, et al,. (2007). An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 32: 179-188. (Pubitemid 46198741)
-
(2007)
Amino Acids
, vol.32
, Issue.2
, pp. 179-188
-
-
Ossowska, K.1
Konieczny, J.2
Wardas, J.3
Pietraszek, M.4
Kuter, K.5
Wolfarth, S.6
Pilc, A.7
-
27
-
-
79953042017
-
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors
-
Pérez-Rial S, García-Gutiérrez MS, Molina JA, Pérez-Nievas BG, Ledent C, Leiva C, et al,. (2010). Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging 32: 631-645.
-
(2010)
Neurobiol Aging
, vol.32
, pp. 631-645
-
-
Pérez-Rial, S.1
García-Gutiérrez, M.S.2
Molina, J.A.3
Pérez-Nievas, B.G.4
Ledent, C.5
Leiva, C.6
-
28
-
-
33847643198
-
9-tetrahydrocannabivarin in mice in vivo
-
DOI 10.1038/sj.bjp.0707124, PII 0707124
-
9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586-594. (Pubitemid 46355554)
-
(2007)
British Journal of Pharmacology
, vol.150
, Issue.5
, pp. 586-594
-
-
Pertwee, R.G.1
Thomas, A.2
Stevenson, L.A.3
Ross, R.A.4
Varvel, S.A.5
Lichtman, A.H.6
Martin, B.R.7
Razdan, R.K.8
-
29
-
-
77249168348
-
Levodopa in Parkinson's disease: From the past to the future
-
Pezzoli G, Zini M, (2010). Levodopa in Parkinson's disease: from the past to the future. Expert Opin Pharmacother 11: 627-635.
-
(2010)
Expert Opin Pharmacother
, vol.11
, pp. 627-635
-
-
Pezzoli, G.1
Zini, M.2
-
30
-
-
20944435840
-
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients [2]
-
DOI 10.1002/ana.20462
-
Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, et al,. (2005). High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777-779. (Pubitemid 40628874)
-
(2005)
Annals of Neurology
, vol.57
, Issue.5
, pp. 777-779
-
-
Pisani, A.1
Fezza, F.2
Galati, S.3
Battista, N.4
Napolitano, S.5
Finazzi-Agro, A.6
Bernardi, G.7
Brusa, L.8
Pierantozzi, M.9
Stanzione, P.10
Maccarrone, M.11
-
31
-
-
66449132820
-
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
-
Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernández E, et al,. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29: 2177-2186.
-
(2009)
Eur J Neurosci
, vol.29
, pp. 2177-2186
-
-
Price, D.A.1
Martinez, A.A.2
Seillier, A.3
Koek, W.4
Acosta, Y.5
Fernández, E.6
-
32
-
-
0035077354
-
Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: An animal model of Parkinson's disease
-
DOI 10.1016/S0166-4328(01)00168-1, PII S0166432801001681
-
Rodriguez Diaz M, Abdala P, Barroso-Chinea P, Obeso J, González-Hernández T, (2001). Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav Brain Res 122: 79-92. (Pubitemid 32238177)
-
(2001)
Behavioural Brain Research
, vol.122
, Issue.1
, pp. 79-92
-
-
Rodriguez Diaz, M.1
Abdala, P.2
Barroso-Chinea, P.3
Obeso, J.4
Gonzalez-Hernandez, T.5
-
33
-
-
0033621366
-
1 receptor mRNA levels in the caudate-putamen
-
DOI 10.1016/S0024-3205(99)00618-9, PII S0024320599006189
-
1 receptor mRNA levels in the caudate-putamen. Life Sci 66: 485-494. (Pubitemid 30062921)
-
(2000)
Life Sciences
, vol.66
, Issue.6
, pp. 485-494
-
-
Romero, J.1
Berrendero, F.2
Perez-Rosado, A.3
Manzanares, J.4
Rojo, A.5
Fernandez-Ruiz, J.J.6
De Yebenes, J.G.7
Ramos, J.A.8
-
34
-
-
0033538482
-
Motor actions of cannabinoids in the basal ganglia output nuclei
-
DOI 10.1016/S0024-3205(99)00293-3, PII S0024320599002933
-
Sañudo-Peña MC, Tsou K, Walker JM, (1999). Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65: 703-713. (Pubitemid 29362776)
-
(1999)
Life Sciences
, vol.65
, Issue.6-7
, pp. 703-713
-
-
Sanudo-Pena, M.C.1
Tsou, K.2
Walker, J.M.3
-
35
-
-
0344406282
-
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease
-
DOI 10.1002/mds.10312
-
Segovia G, Mora F, Crossman AR, Brotchie JM, (2003). Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 18: 138-149. (Pubitemid 36305456)
-
(2003)
Movement Disorders
, vol.18
, Issue.2
, pp. 138-149
-
-
Segovia, G.1
Mora, F.2
Crossman, A.R.3
Brotchie, J.M.4
-
37
-
-
28444433385
-
2 receptor antagonist
-
DOI 10.1038/sj.bjp.0706414, PII 0706414
-
9- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926. (Pubitemid 41722163)
-
(2005)
British Journal of Pharmacology
, vol.146
, Issue.7
, pp. 917-926
-
-
Thomas, A.1
Stevenson, L.A.2
Wease, K.N.3
Price, M.R.4
Baillie, G.5
Ross, R.A.6
Pertwee, R.G.7
|